Genomic predictive biomarkers to anti-HER2 targeted therapies: a combined analysis of CALGB 40601 (Alliance) and PAMELA clinical trials
- Citation:
- J Clin Oncol vol 37 (15_suppl) 571-571
- Meeting Instance:
- ASCO 2019
- Year:
- 2019
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Meta-Analysis
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epub
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- No
- Parents:
- None
- Children:
- 3314
- Pharmas:
- GSK
- Grants:
- U10CA180821, U10CA180882, U24CA196171
- Corr. Author:
- Authors:
- Aranzazu Fernandez-Martinez Maki Tanioka Cheng Fan Joel S. Parker Katherine A. Hoadley Ian Krop Javier Cortes Antonio Llombart-Cussac Paolo Nuciforo Patricia Galván Tomás Pascual Ann Patridge Aleix Prat Charles Perou Lisa Carey
- Networks:
- LAPS-CT018, LAPS-NC007
- Study
- CALGB-40601
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: